Cargando…
Efficiency of BRCAPRO and Myriad II mutation probability thresholds versus cancer history criteria alone for BRCA1/2 mutation detection
Considerable differences exist amongst countries in the mutation probability methods and thresholds used to select patients for BRCA1/2 genetic screening. In order to assess the added value of mutation probability methods, we have retrospectively calculated the BRCAPRO and Myriad II probabilities in...
Autores principales: | van Harssel, J. J. T., van Roozendaal, C. E. P., Detisch, Y., Brandão, R. D., Paulussen, A. D. C., Zeegers, M., Blok, M. J., Gómez García, E. B. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2871096/ https://www.ncbi.nlm.nih.gov/pubmed/19949876 http://dx.doi.org/10.1007/s10689-009-9305-1 |
Ejemplares similares
-
Validation of three BRCA1/2 mutation-carrier probability models Myriad, BRCAPRO and BOADICEA in a population-based series of 183 German families
por: Schneegans, S. M., et al.
Publicado: (2011) -
BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families
por: Antoniou, Antonis C, et al.
Publicado: (2006) -
BRCA1 c.4987-3C>G is a pathogenic mutation
por: Brandão, Rita D., et al.
Publicado: (2011) -
Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
por: Hong, Joohyun, et al.
Publicado: (2021) -
Recent Enhancements to the Genetic Risk Prediction Model BRCAPRO
por: Mazzola, Emanuele, et al.
Publicado: (2015)